In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aerpio Pharmaceuticals Inc.

www.aerpio.com

Latest From Aerpio Pharmaceuticals Inc.

Finance Watch: Phathom IPO Meets Pricing Goal; Cabaletta, TFF Offerings Go Low

Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.

Financing Business Strategies

Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances

In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.

Deals Financing

TIME-2b Disappointed: Aerpio’s Lead Product Fails In Diabetic Retinopathy

As its lead product fails at Phase IIb in diabetic retinopathy, Aerpio’s attentions turn to its other potential indications, but investors will need more convincing that this strategy will pay dividends.

Clinical Trials Companies

Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?

Public Company Edition: Is the IPO bubble getting ready to burst? It's anybody's guess, but biopharma companies are forging ahead, having launched 11 first-time offerings during the past week and a half. Also, Heron leads recent follow-on offerings with a $200m stock sale to fund what may soon be its third commercial product.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Ophthalmic
  • Alias(es)
  • Aerpio Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aerpio Pharmaceuticals Inc.
  • Senior Management
  • Stephen Hoffman, MD, PhD, CEO
    Michael Rogers, CFO
    Kevin Peters, CSO
    Joseph H Gardner, PhD, Pres.
  • Contact Info
  • Aerpio Pharmaceuticals Inc.
    Phone: (513) 985-1920
    9987 Carver Rd.
    Ste. 420
    Cincinnati, OH 45242
    USA
UsernamePublicRestriction

Register